fludarabine
information and resources from the National Cancer Institute
NCI Thesaurus | fludarabine
A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. NCI Thesaurus | fludarabine
A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.
Fludara
Palliative treatment of patients with B-cell lymphocytic leukemia (CLL) who have not responded or have progressed during treatment with at least one standard alkylating agent containing regimen.
Berlex Laboratories Inc. Apr 18 1991
|
|
|
|
news articles
Up-Front Reduced Intensity Allogeneic Stem Cell Transplant May ... Mar 30, 2006
Cancer Consultants (press release), ...aplastic from induction chemotherapy. Conditioning for transplant consisted of a fludarabine-based regimen. Seventeen of 26 patients ...
Natco Pharma launches cancer drug Mar 7, 2006
Sify, In a release here on Tuesday, the company said Lymfuda (Fludarabine) is an alkylating agent useful in the treatment of chronic lymphocytic leukaemia (CLL). ...
Genasense(R) New Drug Application Accepted for Review by FDA Mar 1, 2006
Yahoo! News (press release) The NDA proposes the use of Genasense plus fludarabine and cyclophosphamide for the treatment of patients with relapsed or refractory chronic lymphocytic ...
Genta Incorporated Announces Fourth Quarter and Year End 2005 ... Mar 10, 2006
PR Newswire (press release), ...the Company submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the use of Genasense plus fludarabine and cyclophosphamide ...
Supergen Announces Results from Combination Study in Cll Published ... Mar 14, 2006
PharmaLive.com (press release), ...response (NR) and 15 PRs (47%). In fludarabine- refractory patients, 75% responded. Toxicity levels were acceptable, with grade ...
Genta and Emisphere Technologies Enter into Exclusive Worldwide ... Mar 23, 2006
Yahoo! News (press release) The Company has submitted a New Drug Application (NDA) to the US Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide ...
FDA accepts Genta's application Mar 1, 2006
MarketWatch Genasense would be used in combination with the chemotherapy drugs fludarabine and cyclophosphamide. Genta filed the application with the FDA in late December. ...
Today's Early Winners and Losers Mar 1, 2006
TheStreet.com The company wants to use Genasense, which has had a rocky history, along with fludarabine and cyclophosphamide for treating patients with relapsed or ...
FDA to review Genta drug in leukemia indication Mar 2, 2006
Pharmaceutical Business Review The company is seeking approval for the use of Genasense plus fludarabine and cyclophosphamide for the treatment of patients with relapsed or refractory ...
Genta Posts Q4 Loss On Lower Revenues - Update Mar 10, 2006
Trading Markets, ...in December 2005, it submitted a New Drug Application to the US Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide as ...
BioCryst Initiates Intravenous Peramivir Phase I Clinical Trial Mar 9, 2006
International News Service, ...the Phase I/II trial of Fodosine(TM) for treatment of patients with B-cell ALL and the Phase II trial of Fodosine(TM) for advanced fludarabine-refractory CLL ...
Genta leukemia drug accepted for review Mar 1, 2006
United Press International ...said it is seeking approval of the injectable treatment from the Food and Drug Administration for use with chemotherapy agents fludarabine and cyclophosphamide ...
LAWSUIT SETTLED; US Pays $450,000 for Drug-Study Death Mar 3, 2006
International News Service, NIH scientists wanted to see whether a potent chemotherapy drug that suppresses the immune system, fludarabine, would help lupus patients. ...
Genta to have Genasense decision by fall Mar 1, 2006
BusinessWeek ...its marketing application for Genasense to treat chronic lymphocytic leukemia in conjunction with two chemotherapy drugs fludarabine and cyclophosphamide. ...
Pilot Clinical Study of Genasense Plus Rituxan and Fludarabine ... Dec 12, 2005
PharmaLive.com (press release), ...clinical results regarding the use of its lead anticancer compound, Genasense(R) (oblimersen sodium) Injection, in combination with fludarabine plus rituximab ...
New Treatment Regimen May Improve Mantle Cell Lymphoma: Presented ... Dec 14, 2005
DG News ...a monoclonal antibody with an attached radioactive substance (yttrium), along with standard chemotherapy for MCL including fludarabine, cyclophosphamide, and ...
Treatment with Subcutaneous (SC) MabCampath(R) (alemtuzumab) is ... Dec 12, 2005
PR Newswire UK (press release), ...is both effective and well-tolerated when compared to historical series of patients receiving intravenous (IV) therapy for fludarabine-refractory chronic ...
Chemotherapy Consolidation with Zevalin(R) (90Y-Ibritumomab ... Dec 12, 2005
PR Newswire UK (press release), ...to complete response (CR) with no palpable lymph nodes or measurable masses on CT scans following treatment with Zevalin after fludarabine-based chemotherapy ...
Point Therapeutics Announces Positive Interim Results at American ... Dec 12, 2005
Business Wire (press release), This single-arm trial evaluates talabostat in combination with rituximab in up to 54 evaluable patients with advanced CLL who have failed fludarabine and/or ...
New Study Reinforces Increased Life Expectancy with MabCampath(R) ... Dec 13, 2005
PR Newswire UK (press release), In addition, the median survival for all patients was approximately 20 (exact: 19.6) months; 15 months for fludarabine-refractory patients (n=67) and 31 months ...
Genta study sees Genasense combo benefit Dec 12, 2005
BusinessWeek ...a late-stage clinical trial, researchers found that the addition of Genasense to a treatment regimen using the anticancer drugs fludarabine and cyclophosphamide ...
SUPG: Nipent Studies Presented at ASH Dec 9, 2005
PharmaLive.com (press release), A combination regimen of pentostatin, cyclophosphamide and rituximab (PCR) is suggested to have comparable activity to fludarabine, cyclophosphamide, and ...
ASH: Experimental Chemotherapy Drug Effective Against Resistant ... Dec 14, 2005
MedPage Today, ...toxicity in patients with refractory indolent and mantle cell NHL, including patients that previously failed alkylating and fludarabine-containing regimens ...
BioCryst Announces $30.0 Million Common Stock Offering to ... Dec 15, 2005
PR Newswire (press release), I trial of Fodosine(TM) for treatment of patients with cutaneous T-cell lymphoma and the Phase II trial of Fodosine(TM) for advanced fludarabine-refractory CLL ...
Annual Meeting of the American Society of Hematology Highlights ... Dec 6, 2005
PR Newswire (press release), 2005: Abstract 2129 Title: "Efficacy and Safety of the Combination of Genasense (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab ...
BioCryst Announces Presentation of Fodosine(TM) Data During the ... Dec 12, 2005
Yahoo! News (press release) These promising results have led to initiation of a Phase II study of oral Fodosine(TM) in patients with advanced, fludarabine-refractory CLL, the first trial ...
Advances in Radiotherapy Show Benefit for High-Risk Elderly ... Dec 12, 2005
PR Newswire (press release), Further follow-up and additional patients will help confirm the durability of these findings." 131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body ...
Annual Meeting of the American Society of Hematology Highlights ... Dec 6, 2005
PR Newswire (press release), Title: "Efficacy and Safety of the Combination of Genasense (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously ...
(PRN) - Option Recognized as a Red Herring Small Cap 100 ... [+] Dec 12, 2005
Bolsamania.com, ...[+]. (PRN) - Treatment with Subcutaneous (SC) MabCampath(R) (alemtuzumab) is Effective and Safe for Patients Suffering from Fludarabine-Refractory CLL ... [+. ...
Advances in Radiotherapy Show Benefit for High-Risk Elderly ... Dec 12, 2005
PharmaLive.com (press release), The study was designed to estimate the maximum tolerated dose of 131I-anti-CD45 antibody when combined with fludarabine (FLU) and low-dose total body ...
TESTICULAR CANCER MOSTLY A YOUNG MAN'S CANCER Nov 22, 2005
Charlotte Sun-Herald, ...years. When and if treatment becomes necessary, one of two chemotherapy drugs is usually chosen -- chlorambucil or fludarabine. ...
Nipent®/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... Nov 23, 2005
Cancer Consultants (press release), November. One of the most active drug combinations for the treatment of CLL is Fludara® (fludarabine), Cytoxan and Rituxan. The ...
|
|
